Cell Therapy Archives | Page 43 of 60

Pediatric Stem Cell Transplantation Expert and Industry Leader Dr. Joseph Rosenthal Joins Cell Source’s Scientific Advisory Board

February 25, 2021 By Cade Hildreth, Founder & President Leave a Comment

Director of Pediatric Hematology-Oncology and Barron Hilton Professor & Chair in Pediatrics at City of Hope National Medical Center Brings Decades of Innovation to Cell Source’s Scientific Leadership Team

February 25, 2021 – New York, NY – Cell Source, Inc. (OTC: CLCS) (“Cell Source” or the “Company”), a developer of Veto Cell-based innovative immunotherapy technologies that facilitate mismatched donor stem cell (e.g. bone marrow) and organ transplants and other cell therapy treatments with an improved safety profile achieved through the active management of immune response, today announced that Joseph Rosenthal, M.D., M.H.C.M. JD, has joined its Scientific Advisory Board. Dr. Rosenthal is currently the Director of Pediatric Hematology-Oncology and Barron Hilton Professor & Chair in Pediatrics at City of Hope National Medical Center in Duarte, CA. [Read more…]

CAR-T Financing Frenzy: $100 Billion in Market Cap by CAR-T Companies

February 19, 2021 By Cade Hildreth, Founder & President Leave a Comment

CAR-T funding is on the rise. At first the trend was subtle, but the tide has swelled as CAR-T therapies like Kymriah, Yescarta, Tecartus and Breyanzi have reached the marketplace and created a CAR-T funding craze. CAR-T start-ups have been richly funded by investors eager to get into this trending area of regenerative medicine. [Read more…]

Dr. Robert Hariri – Placental Pioneer Launches Celularity with $250M Cash

February 15, 2021 By Cade Hildreth, Founder & President 6 Comments

Dr. Robert Hariri, CEO of Celularity, Inc.

Dr. Robert Hariri is a fascinating figure in the stem cell industry, because he was the earliest pioneer to recognize the regenerative potential of the human placenta. In August 2017, Hariri brought his latest company, Celularity, into the spotlight by announcing a successful Series A financing with contributions from influential investors, including United Therapeutics Corporation, Celgene, Sorrento Therapeutics, and Human Longevity, Inc. (HLI).

Today, Celularity’s investor contributions have reached an astounding $250 million, including contributions from the Genting Group, Dreyfus Family Office and Tony Robbins, among other notable investors.

Celularity, Inc.

Celularity, a spin-out company from global biopharmaceutical giant Celgene, announced this morning that it has raised $250 million to support development of revolutionary placental-derived products, including T-cells that will be immune advantaged because of their derivation from the placenta. This is a massive accomplishment, because it dwarfs the $225 million in Series A financing raised by BlueRock Therapeutics in December 2016 that was previously a landmark accomplishment within the stem cell industry.

With the Celgene snagging Juno Therapeutics for a shocking $9 billion in January 2018 and Gilead picking up Kite Pharma for an astounding $11.9 billion in August 2017, Celularity is also joining the ranks of powerful immunotherapy companies that could be a target for merger or acquisition.

If that wasn’t enough, Celularity is looking to burst a major bottleneck in the industry by deriving T-cells from a single (allogeneic) cell line, potentially positioning itself to slash the price point for CAR-T treatments. Currently, Gilead and subsidiary Kite Pharma have a CAR-T cell therapy on the market (Yescarta) with a price point of $373,000 per patient and Novartis has a genetically modified autologous CAR-T therapy (Kymriah) priced at $475,000 per treatment.

At its core, Celularity is a biotechnology company that specializes in leveraging biologically active cell populations within the postpartum human placenta. Founded on the pioneering work of Robert Hariri, MD, PhD, in human placenta-derived cellular therapeutics and biomaterials, Celularity is uniquely positioned to harness the potential of most biocreative event on earth: human birth. [Read more…]

The Complete Guide To Virtual Stem Cell Conferences in 2021

January 22, 2021 By Cade Hildreth, Founder & President Leave a Comment

As the world has been rocked by the COVID-19 pandemic, most in-person conferences have been canceled or switched to online formats. This goes for stem cell conferences too. However, stem cell conferences are still happening in 2021, albeit mostly virtual.

Here is your complete guide to virtual stem cell conferences in 2021. Learn more below to decide which ones to attend. For ease of reference, they are organized by date. [Read more…]

Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy

January 14, 2021 By Cade Hildreth, Founder & President Leave a Comment

FLORHAM PARK, N.J. and NEW YORK, Jan. 8, 2021 — Celularity, Inc. (“Celularity”), a clinical-stage biotechnology company, leading the next evolution in cellular medicine with the development of off-the-shelf allogeneic therapies derived from the postpartum human placenta, and GX Acquisition Corp. (Nasdaq: GXGX), a special purpose acquisition company, today announced they have entered into a definitive merger agreement pursuant to which GX Acquisition Corp. will combine with Celularity. Upon the closing of the transaction, which is expected to occur in the second quarter of 2021, GX Acquisition Corp. will be renamed Celularity Inc., and its common stock and warrants are expected to remain listed on Nasdaq under the new ticker symbols “CELU” and “CELUW.” [Read more…]